Subjective wellbeing under quetiapine treatment: Effect of diagnosis, mood state, and anxiety

Schizophrenia Research

Volumn 110, Issue 1-3, 2009, Pages 72-79

  Lambert, Martin ^a   Naber, Dieter ^a   Karow, Anne ^a   Huber, Christian G ^a   Köhler, Jürgen ^b   Heymann, Joachim ^b   Schimmelmann, Benno G ^c  

^a Centre for Psychosocial Medicine   (Germany)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Bipolar disorder; Quality of life; Quetiapine; Schizophrenia; Subjective wellbeing

Indexed keywords

NEUROLEPTIC AGENT; QUETIAPINE;

ADULT; ANXIETY; ARTICLE; BIPOLAR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DIAGNOSIS; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANIA; MOOD; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUBJECTIVE WELLBEING UNDER NEUROLEPTIC TREATMENT SCALE; WELLBEING;

ADULT; AFFECT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; ANXIETY; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; OUTPATIENTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 64749099762     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.03.004     Document Type: Article

References (39)

1. Albert U., Rosso G., Maina G., and Bogetto F. Impact of anxiety disorder comorbidity on quality of life in euthymic bipolar disorder patients: differences between bipolar I and II subtypes. J. Affect. Disord. 105 (2008) 297-303
2. Benabarre A., Vieta E., Colom F., Martínez-Arán A., Reinares M., and Gastó C. Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences. Eur. Psychiatr. 16 (2001) 167-172
3. Braga R.J., Mendlowicz M.V., Marrocos R.P., and Figueira I.L. Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life. J. Psychiatr. Res. 39 (2005) 409-414
4. Chand P.K., Mattoo S.K., and Sharan P. Quality of life and its correlates in patients with bipolar disorder stabilized on lithium prophylaxis. Psychiatry Clin. Neurosci. 58 (2004) 311-318
5. De Haan L., Weisfelt M., Dingemans P.M., Linszen D.H., and Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (Berl) 162 (2002) 24-28
6. de Haan L., Nimwegen L., Amelsvoort T., Dingemans P., and Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 41 4 (2008) 125-128
7. Dilsaver S.C., Chen Y.R., Shoaib A.M., and Swann A.C. Phenomenology of mania: evidence for distinct depressed, dysphoric, and euphoric presentations. Am. J. Psychiatry 156 (1999) 426-430
8. Dittmann V., and Dilling H. Chapter V (F) of ICD-10: mental, behavioural and developmental disorders - introduction and overview. Pharmacopsychiatry 23 suppl 4 (1990) 137-141
9. Dorée J.P., Des Rosiers J., Lew V., Gendron A., Elie R., Stip E., and Tourjman S.V. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr. Med. Res. Opin. 23 (2007) 333-341
10. Gaebel, W., Falkai, P., 2000. Praxisleitlinien in Psychiatrie und Psychotherapie: Behandlungsleitlinie Affektive Erkrankungen. Steinkopff Verlag Darmstadt.
11. Gaebel, W., Falkai, P., 2006. Praxisleitlinien in Psychiatrie und Psychotherapie: Behandlungsleitlinie Schizophrenie. Steinkopff Verlag Darmstadt.
12. Gazalle F.K., Andreazza A.C., Hallal P.C., Kauer-Sant'anna M., Ceresér K.M., Soares J.C., Santin A., and Kapczinski F. Bipolar depression: the importance of being on remission. Rev. Bras. Psiquiatr. 28 (2006) 93-96
13. Gazalle F.K., Hallal P.C., Andreazza A.C., Frey B.N., Kauer-Sant'Anna M., Weyne F., da Costa S.C., Santin A., and Kapczinski F. Manic symptoms and quality of life in bipolar disorder. Psychiatry Res. 153 (2007) 33-38
14. Gupta S., Steinmeyer C.H., Lockwood K., Lentz B., and Schultz K. Comparison of older patients with bipolar disorder and schizophrenia/schizoaffective disorder. Am. J. Geriatr. Psychiatry 15 (2007) 627-633
15. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338 (1976), National Institut of Mental Health, Rockville Md 218-222
16. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., Rodriguez M.J., Rele R., Orta J., Kharbeng A., Araya S., Gervin M., Alonso J., Mavreas V., Lavrentzou E., Liontos N., Gregor K., Jones P.B., and SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. 107 suppl. 416 (2003) 16-23
17. Hirschfeld R.M., Weisler R.H., Raines S.R., Macfadden W., and for the BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 67 (2006) 355-362
18. Huppert J.D., Weiss K.A., Lim R., Pratt S., and Smith T.E. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr. Res. 51 (2001) 171-180
19. Karow A., Moritz S., Lambert M., Schoder S., and Naber D. PANSS syndromes and quality of life in schizophrenia. Psychopathology 38 (2005) 320-326
20. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., Lambert M., Schimmelmann B.G., and Naber D. Association of subjective wellbeing, symptoms and side effects with compliance after 12 month treatment in schizophrenia. J. Clin. Psychiatry 68 (2007) 75-80
21. Kauer-Sant'Anna M., Frey B.N., Andreazza A.C., Ceresér K.M., Gazalle F.K., Tramontina J., da Costa S.C., Santin A., and Kapczinski F. Anxiety comorbidity and quality of life in bipolar disorder patients. Can. J. Psychiatry 52 (2007) 175-181
22. Keating G.M., and Robinson D.M. Quetiapine: a review of its use in the treatment of bipolar depression. Drugs 67 (2007) 1077-1095
23. Keller M.B. Prevalence and impact of comorbid anxiety and bipolar disorder. J. Clin. Psychiatry 67 suppl 1 (2006) 5-7
24. Lambert M., Schimmelmann B., Naber D., Schacht A., Karow A., Wagner T., and Czekalla J. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective wellbeing in 2960 patients with schizophrenia. J. Clin. Psychiatry 67 (2006) 1690-1697
25. Lambert M., Reimitz P.E., and Naber D. Clinical effectiveness of quetiapine: findings of a post-marketing surveillance study in patients with schizophrenia. Int. J. Psychiatry Clin. Pract. 10 (2006) 204-212
26. Lambert M., Eich F.X., Schacht M., Linden M., and Schimmelmann B.G. Remission of severely impaired subjective well-being in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr. Scand. 115 (2007) 106-113
27. Lambert M., Naber D., Schacht A., Wagner T., Huber C., Karow A., and Schimmelmann B. Predicting remission and recovery in 392 never-treated patients with schizophrenia. Acta Psychiatr. Scand. 118 (2008) 220-229
28. Lambert M., Schimmelmann B.G., Schacht A., Karow A., Wagner T., Wehmeier P., Huber C.G., Dittmann R.W., Hundemer H.-P., and Naber D. Long-term cluster of subjective wellbeing in schizophrenia: prediction of cluster affiliation and their predictive value for recovery in 2842 patients followed over 3 years. Schizophr. Res. 107 (2009) 165-172
29. Mallinckrodt C.H., Clark W.S., and David S.R. Accounting for dropout bias using mixed-effects models. J. Biopharm. Stat. 11 (2001) 9-21
30. Mallinckrodt C.H., Kaiser C.J., Watkin J.G., Molenberghs G., and Carroll R.J. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin. Trials 1 (2004) 477-489
31. Naber, D., Moritz, S., Lambert, M., Pajonk, F.G., Holzbach, R., Mass, R., Andresen, B., 2001. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 50, 79-88.
32. Perkins, D.O., Johnson, J.L.,Hamer, R.M., Zipursky, R.B.,Keefe, R.S., Centorrhino, F., Green, A.I., Glick, I.B., Kahn, R.S., Sharma, T., Tohen,M., McEvoy, J.P.,Weiden, P.J., Lieberman, J.A., HGDH Research Group, 2006. Predictors of antipsycho- tic medication adherence in patients recovering from a first psychotic episode. Schizophr. Res. 83, 53-63.
33. Prieto L., Novick D., Sacristan J.A., and SOHO Study Group. A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatr. Scand. 107 suppl. 416 (2003) 24-29
34. Schimmelmann B.G., Paulus S., Schacht M., Tilgner C., Schulte-Markwort M., and Lambert M. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J. Child Adolesc. Psychopharmacol. 15 (2007) 249-258
35. Simon G.E., Bauer M.S., Ludman E.J., Operskalski B.H., and Unützer J. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J. Clin. Psychiatry 68 (2007) 1237-1245
36. Torrent C., Martínez-Arán A., and Amann B. Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic bipolar and healthy subjects. Acta Psychiatr. Scand. 116 (2007) 453-460
37. Wehmeier P.M., Kluge M., Schacht A., Helsberg K., and Schreiber W. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr. Res. 91 (2007) 178-186
38. Wehmeier P.M., Kluge M., Schneider E., Schacht A., Wagner T., and Schreiber W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 30 (2007) 703-712
39. Zhang H., Wisniewski S.R., Bauer M.S., Sachs G.S., Thase M.E., and Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Investigators. Comparisons of perceived quality of life across clinical states in bipolar disorder: data from the first 2000 Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) participants. Compr. Psychiatry 47 (2006) 161-168